GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Primary Objectives:

To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Mantle Cell Lymphoma
DRUG: Pirtobrutinib|DRUG: Rituximab|DRUG: Venetoclax
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0, Through study completion; an average of 1 year.
Secondary Objectives:

* To evaluate the objective response rate to PRV combination therapy in patients with previously untreated MCL.
* To evaluate the duration of response in patients with an objective response to PRV combination therapy.
* To evaluate the progression-free survival and overall survival in patients treated with PRV combination therapy.
* To evaluate the safety profile of PRV combination therapy in patients with previously untreated MCL.